Newstral
Alkermes
- BAlkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.barrons.com
- MFDA told Alkermes to stop publishing Vivitrol admarketwatch.com
- Strong Q3 Results Drive Guardant’s Stock 15% Higher In 20 DaysForbes
- Why Is Alkermes Stock Down 30% So Far This Year?Forbes
- Struggling drugmaker Alkermes buys Boston biotechbizjournals.com
- BBiogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.barrons.com
- Drugmaker Alkermes cuts 160 jobs in effort to lower expensesbizjournals.com
- Employers have a critical role in fighting Kentucky’s opioid epidemickentucky.com
- FDA rejects Alkermes' depression drug, questions effectivenessbizjournals.com
- Alkermes shares dip despite 'positive' trial results from schizophrenia drugbizjournals.com
- Alkermes depression drug in peril after FDA advisory votebizjournals.com
- Vivitrol Therapy Gives Those In Recovery A Shot At Lifelongislandpress.com
- ASAP Rally for Recovery is Saturday at Eastwood FieldThe Vindicator
- New drug program for addiction at jailwschronicle.com
- Drugmaker Alkermes confirms expansion, hiring plans in Walthambizjournals.com
- Alkermes investors take $1.8B bath as FDA nixes depression drug applicationbizjournals.com
- Opioid addiction drug maker Alkermes expands in Walthambizjournals.com
- TScientists study effectiveness of opioid treatmentsthetartan.org
- Study Finds Competing Opioid Treatments Have Similar OutcomesThe New York Times
- BERKO: Alkermes’ medicine and IBM’s quantum computing mecktimes.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.